Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma (clinicaltrials.gov) - Sep 30, 2026 - P2 | N=35 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting
Enrollment open • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Oncology • Splenic Marginal Zone Lymphoma
|